Astghik Voskanyan

Yerevan, ER, Armenia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

DOSE-DEPENDENT PROTECTIVE EFFECTS OF TAURINE IN EXPERIMENTAL ENVENOMATION BY THE BLUNT-NOSED VIPER (MACROVIPERA LEBETINA OBTUSA).

DOSE-DEPENDENT PROTECTIVE EFFECTS OF TAURINE IN EXPERIMENTAL ENVENOMATION BY THE BLUNT-NOSED VIPER (MACROVIPERA LEBETINA OBTUSA).

Journal: Georgian medical news
Published: March 10, 2026

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.

Journal: Leukemia
Published: October 30, 2025

Understanding the causes of high mortality among adult acute leukaemia patients in Armenia.

Understanding the causes of high mortality among adult acute leukaemia patients in Armenia.

Journal: Ecancermedicalscience
Published: November 19, 2024

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program.

Journal: Discover oncology
Published: September 29, 2024

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting.

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting.

Journal: Oncology (Williston Park, N.Y.)
Published: March 22, 2024

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.

Journal: Leukemia
Published: September 14, 2023

Impact of emerging ACA on survival in chronic myeloid leukemia (CML).

Impact of emerging ACA on survival in chronic myeloid leukemia (CML).

Journal: Leukemia
Published: July 23, 2022

Overview of Cancer Control in Armenia and Policy Implications.

Overview of Cancer Control in Armenia and Policy Implications.

Journal: Frontiers in oncology
Published: September 24, 2021

Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML.

Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML.

Journal: Leukemia
Published: September 11, 2020

High-risk additional chromosomal abnormalities at low blast counts herald death by CML.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML.

Journal: Leukemia
Published: February 27, 2020

Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.

Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.

Journal: PloS one
Published: October 25, 2018

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Journal: Leukemia
Published: June 23, 2017
Showing 1-12 of 14

Last Updated: 09/26/2026